PE20190436A1 - Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 - Google Patents
Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1Info
- Publication number
- PE20190436A1 PE20190436A1 PE2018002326A PE2018002326A PE20190436A1 PE 20190436 A1 PE20190436 A1 PE 20190436A1 PE 2018002326 A PE2018002326 A PE 2018002326A PE 2018002326 A PE2018002326 A PE 2018002326A PE 20190436 A1 PE20190436 A1 PE 20190436A1
- Authority
- PE
- Peru
- Prior art keywords
- binding
- polypeptide
- tnf family
- antigen
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a una molecula de union a antigeno que contiene trimero de ligando de la familia de TNF (Factor de Necrosis Tumoral) que comprende al menos un resto capaz de unirse especificamente a PD1 (proteina de muerte programada 1) y un primer y un segundo polipeptido unidos entre si por un enlace disulfuro (el primer polipeptido tiene 2 ectodominios de un miembro de la familia de ligandos de TNF o un fragmento del mismo, conectados entre si por un enlazador peptidico, mientras que el segundo polipeptido tiene un ectodominio de dicho miembro de la familia de ligandos de TNF o un fragmento del mismo), asi como a un polinucleotido aislado que codifica la molecula descrita lineas arriba (puede estar comprendido en un vector de expresion o en una celula hospedadora), y a composiciones farmaceuticas que contienen la molecula o un derivado (pueden ser 1 o mas y se puede anadir un agente terapeutico adicional) y al menos un excipiente farmaceuticamente aceptable (disolventes, tensioactivos, antioxidantes, entre otros). Tambien se refiere a ensayos para estudiar sus propiedades fisicas y quimicas y/o actividades biologicas, y metodos de produccion, recombinantes, terapeuticos y de tratamiento. La presente invencion es util para el tratamiento del cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16169487.2A EP3243832A1 (en) | 2016-05-13 | 2016-05-13 | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190436A1 true PE20190436A1 (es) | 2019-03-27 |
Family
ID=56014831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018002326A PE20190436A1 (es) | 2016-05-13 | 2017-05-11 | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 |
Country Status (22)
Country | Link |
---|---|
US (2) | US20190185566A1 (es) |
EP (2) | EP3243832A1 (es) |
JP (1) | JP6801006B2 (es) |
KR (1) | KR20190004802A (es) |
CN (1) | CN109563146B (es) |
AR (1) | AR108453A1 (es) |
AU (1) | AU2017264548A1 (es) |
BR (1) | BR112018073289A2 (es) |
CA (1) | CA3023393A1 (es) |
CL (1) | CL2018003205A1 (es) |
CO (1) | CO2018012083A2 (es) |
CR (1) | CR20180538A (es) |
IL (1) | IL262843A (es) |
MA (1) | MA44973A (es) |
MX (1) | MX2018013675A (es) |
PE (1) | PE20190436A1 (es) |
PH (1) | PH12018502367A1 (es) |
RU (1) | RU2018143439A (es) |
SG (1) | SG11201810076WA (es) |
TW (1) | TW201805306A (es) |
WO (1) | WO2017194641A1 (es) |
ZA (1) | ZA201807581B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
MY192202A (en) | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
CA3131983C (en) | 2015-11-18 | 2023-12-05 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
CA3039446A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
JP7122311B2 (ja) | 2017-01-03 | 2022-08-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗4-1bbクローン20h4.9を含む二重特異性抗原結合分子 |
CA3047708A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirpalpha-41bbl fusion protein and methods of use thereof |
WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
AU2018205888B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A PD1-41BBL fusion protein and methods of use thereof |
WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
WO2018187215A1 (en) * | 2017-04-03 | 2018-10-11 | Merrimack Pharmaceuticals, Inc. | Bispecific 4-1bb agonist molecules |
MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
MY199406A (en) * | 2017-04-05 | 2023-10-25 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
AR114284A1 (es) * | 2018-04-13 | 2020-08-12 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl |
SG11202013167UA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
JP7221379B2 (ja) | 2018-10-01 | 2023-02-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗fapクローン212を含む二重特異性抗原結合分子 |
AU2019410073B2 (en) | 2018-12-21 | 2024-08-01 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
CN110592140A (zh) * | 2019-09-30 | 2019-12-20 | 王清路 | Pd-1基因缺陷型pd-1-cart细胞制剂的制法 |
WO2021140130A1 (en) * | 2020-01-09 | 2021-07-15 | F. Hoffmann-La Roche Ag | New 4-1bbl trimer-containing antigen binding molecules |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
CN115836084A (zh) * | 2020-05-15 | 2023-03-21 | 阿珀吉尼科斯股份公司 | 多特异性免疫调节剂 |
WO2023088876A1 (en) * | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
CN114984207B (zh) * | 2022-05-09 | 2024-01-26 | 浙江特瑞思药业股份有限公司 | 一种抗pd-1纳米抗体制剂 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
JP2005524379A (ja) | 2001-08-03 | 2005-08-18 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性の増強を伴う抗体グリコシル化改変体 |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
EP3287144A1 (en) | 2002-07-03 | 2018-02-28 | ONO Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトpd−1に対し特異性を有する物質 |
JP2007523602A (ja) * | 2003-02-06 | 2007-08-23 | マイクロメット アクツィエン ゲゼルシャフト | 持続的なt細胞応答方法 |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
AU2003272065A1 (en) | 2003-04-03 | 2004-10-25 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
DE602004018141D1 (de) | 2003-07-04 | 2009-01-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
PL2380911T3 (pl) | 2003-11-05 | 2018-10-31 | Roche Glycart Ag | Cząsteczki wiążące antygen o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej |
MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
KR101339628B1 (ko) * | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
EP2397155B1 (en) | 2005-06-08 | 2017-12-13 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
EP2195347A1 (en) | 2007-08-17 | 2010-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating and diagnosing hematologic malignancies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
RU2531758C2 (ru) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Моноклональные антитела для лечения опухолей |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
PL2310509T3 (pl) | 2008-07-21 | 2015-08-31 | Apogenix Ag | Jednołańcuchowe cząsteczki TNFSF |
EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Pd−1特異抗体およびその使用 |
WO2010029434A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
HUE028582T2 (en) | 2008-11-28 | 2016-12-28 | Univ Emory | Method for determining the efficacy of PD-1 antagonists |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
CN103154038B (zh) | 2010-08-13 | 2016-05-11 | 罗切格利卡特公司 | 抗成纤维细胞激活蛋白抗体及使用方法 |
CA2828289C (en) | 2011-03-29 | 2020-07-21 | Roche Glycart Ag | Antibody fc variants |
US9822179B2 (en) * | 2011-04-01 | 2017-11-21 | Universitat Stuttgart | Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
BR112013032552A2 (pt) | 2011-07-24 | 2017-12-12 | Curetech Ltd | variantes de anticorpos monoclonais humanizados imunomoduladores |
JP6357467B2 (ja) * | 2012-04-30 | 2018-07-11 | バイオコン・リミテッド | 標的化された/免疫調節性融合タンパク質およびそれを作製するための方法 |
CA2910278C (en) | 2013-05-02 | 2021-09-28 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
CA2934028A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP3224275B1 (en) * | 2014-11-14 | 2020-03-04 | F.Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
EP3150636A1 (en) * | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
MY192202A (en) * | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
CN109071652B (zh) * | 2016-05-11 | 2022-09-23 | 豪夫迈·罗氏有限公司 | 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子 |
-
2016
- 2016-05-13 EP EP16169487.2A patent/EP3243832A1/en not_active Ceased
-
2017
- 2017-05-11 CR CR20180538A patent/CR20180538A/es unknown
- 2017-05-11 CA CA3023393A patent/CA3023393A1/en not_active Abandoned
- 2017-05-11 PE PE2018002326A patent/PE20190436A1/es unknown
- 2017-05-11 MA MA044973A patent/MA44973A/fr unknown
- 2017-05-11 AR ARP170101253A patent/AR108453A1/es unknown
- 2017-05-11 AU AU2017264548A patent/AU2017264548A1/en not_active Abandoned
- 2017-05-11 CN CN201780038363.6A patent/CN109563146B/zh active Active
- 2017-05-11 EP EP17725542.9A patent/EP3455248B1/en active Active
- 2017-05-11 SG SG11201810076WA patent/SG11201810076WA/en unknown
- 2017-05-11 MX MX2018013675A patent/MX2018013675A/es unknown
- 2017-05-11 RU RU2018143439A patent/RU2018143439A/ru not_active Application Discontinuation
- 2017-05-11 KR KR1020187036101A patent/KR20190004802A/ko not_active Application Discontinuation
- 2017-05-11 WO PCT/EP2017/061241 patent/WO2017194641A1/en unknown
- 2017-05-11 BR BR112018073289-3A patent/BR112018073289A2/pt not_active Application Discontinuation
- 2017-05-11 JP JP2018559781A patent/JP6801006B2/ja active Active
- 2017-05-12 TW TW106115699A patent/TW201805306A/zh unknown
-
2018
- 2018-11-07 IL IL262843A patent/IL262843A/en unknown
- 2018-11-08 CO CONC2018/0012083A patent/CO2018012083A2/es unknown
- 2018-11-09 PH PH12018502367A patent/PH12018502367A1/en unknown
- 2018-11-12 ZA ZA2018/07581A patent/ZA201807581B/en unknown
- 2018-11-12 CL CL2018003205A patent/CL2018003205A1/es unknown
- 2018-11-13 US US16/189,041 patent/US20190185566A1/en not_active Abandoned
-
2022
- 2022-01-28 US US17/649,321 patent/US20230123178A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN109563146A (zh) | 2019-04-02 |
RU2018143439A3 (es) | 2020-08-03 |
MX2018013675A (es) | 2019-04-01 |
SG11201810076WA (en) | 2018-12-28 |
EP3243832A1 (en) | 2017-11-15 |
JP2019524053A (ja) | 2019-09-05 |
PH12018502367A1 (en) | 2019-09-09 |
CL2018003205A1 (es) | 2019-01-18 |
AU2017264548A1 (en) | 2018-11-22 |
CN109563146B (zh) | 2022-10-14 |
CA3023393A1 (en) | 2017-11-16 |
BR112018073289A2 (pt) | 2019-03-19 |
MA44973A (fr) | 2021-04-07 |
EP3455248A1 (en) | 2019-03-20 |
US20230123178A1 (en) | 2023-04-20 |
IL262843A (en) | 2018-12-31 |
CR20180538A (es) | 2019-01-10 |
KR20190004802A (ko) | 2019-01-14 |
RU2018143439A (ru) | 2020-06-15 |
CO2018012083A2 (es) | 2018-11-22 |
US20190185566A1 (en) | 2019-06-20 |
ZA201807581B (en) | 2021-05-26 |
AR108453A1 (es) | 2018-08-22 |
WO2017194641A1 (en) | 2017-11-16 |
TW201805306A (zh) | 2018-02-16 |
EP3455248B1 (en) | 2021-06-30 |
JP6801006B2 (ja) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190436A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1 | |
CO2020000357A2 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
PE20170896A1 (es) | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf | |
CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
CO2019011688A2 (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra cánceres positivos para prame | |
CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
PE20210746A1 (es) | Metodo para el cribado ultrarrapido de la afinidad de complejos mhc-peptido en busca de ligandos de tcr | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
BR112018016281A2 (pt) | molécula biespecífica ativadora de célula t ativável por protease, polipeptídeo idiotipo-específico, composição farmacêutica, usos da molécula biespecífica e método de tratamento de uma doença em um indivíduo | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
AR085198A1 (es) | Composicion farmaceutica | |
PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
CR20170138A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
EA201791853A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака | |
AR087615A1 (es) | Moleculas biespecificas de union a antigeno | |
CL2021001565A1 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407) | |
PE20191662A1 (es) | Anticuerpos anti-il-5 | |
EA201991444A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
AR098953A1 (es) | Anticuerpo anti-adam17 (proteína desintegrina y metaloproteinasa-17) y su uso para el tratamiento de cáncer | |
AR111000A1 (es) | Moléculas de unión biespecíficas que son capaces de unirse a cd137 y a antígenos tumorales, y usos de las mismas | |
EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением |